Nabriva Therapeutics (NASDAQ:NBRV) had its price target decreased by SunTrust Banks to $11.00 in a report published on Wednesday, The Fly reports. SunTrust Banks currently has a buy rating on the biotechnology company’s stock. SunTrust Banks also issued estimates for Nabriva Therapeutics’ Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($2.09) EPS, Q1 2019 earnings at ($0.31) EPS, Q2 2019 earnings at ($0.33) EPS, Q3 2019 earnings at ($0.28) EPS, Q4 2019 earnings at ($0.27) EPS, FY2019 earnings at ($1.20) EPS, FY2020 earnings at ($0.94) EPS, FY2021 earnings at ($0.47) EPS and FY2022 earnings at ($0.03) EPS.
NBRV has been the subject of a number of other reports. Zacks Investment Research downgraded Nabriva Therapeutics from a buy rating to a hold rating in a research report on Saturday, November 10th. ValuEngine upgraded Nabriva Therapeutics from a hold rating to a buy rating in a research report on Thursday, November 1st. BidaskClub upgraded Nabriva Therapeutics from a strong sell rating to a sell rating in a research report on Tuesday, October 2nd. Needham & Company LLC restated a buy rating and issued a $18.00 price target on shares of Nabriva Therapeutics in a research report on Wednesday, July 25th. Finally, Morgan Stanley initiated coverage on Nabriva Therapeutics in a research report on Friday, September 7th. They issued an overweight rating and a $8.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. Nabriva Therapeutics presently has a consensus rating of Buy and an average target price of $10.17.
NBRV traded up $0.05 during trading on Wednesday, reaching $2.05. The company had a trading volume of 240,183 shares, compared to its average volume of 418,437. Nabriva Therapeutics has a 52 week low of $1.84 and a 52 week high of $6.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.35 and a current ratio of 7.35.
Several large investors have recently added to or reduced their stakes in NBRV. JPMorgan Chase & Co. lifted its position in shares of Nabriva Therapeutics by 163.9% during the first quarter. JPMorgan Chase & Co. now owns 24,959 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 15,501 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Nabriva Therapeutics by 4,353.6% during the second quarter. Bank of America Corp DE now owns 55,403 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 54,159 shares during the last quarter. Wedbush Securities Inc. bought a new stake in shares of Nabriva Therapeutics during the second quarter worth $371,000. Clear Harbor Asset Management LLC lifted its position in shares of Nabriva Therapeutics by 1,195.7% during the third quarter. Clear Harbor Asset Management LLC now owns 212,500 shares of the biotechnology company’s stock worth $443,000 after purchasing an additional 196,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Nabriva Therapeutics by 173.2% during the first quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 70,917 shares during the last quarter. Institutional investors and hedge funds own 3.20% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.